Skip to main content

Table 3 Mixed models evaluating modified Rodnan skin score adjusted for disease duration

From: Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis

Effect Estimate (95 % CI) p-value
Disease duration −0.9 (−1.4 to −0.4) 0.0046
Drug, abatacept vs. placebo −9.8 (−16.7 to −3.0) 0.0114
Study visit −0.1 (−1.2 to 0.9) 0.783
Study visit abatacepta −0.9 (−2.2 to 0.4) 0.1773
  1. aRefers to the mixed model taking into account the interaction between visit times and abatacept treatment. CI confidence interval